Selvita opens new research site in Poznan

Krakow, Poland – 10 May 2017 – Selvita (WSE:SLV), one of the largest drug discovery companies in Europe, has opened a new research site in Poznan, Poland. The new site is located in the Wielkopolska Centre of Advanced Technologies and the initial laboratory space which Selvita occupies amounts to 5…

More

Selvita presents at BioTrinity 2017

Kraków, Poland – 04 May 2017 – Selvita will participate, as well as present, at the upcoming BioTrinity 2017 conference, taking place in London, UK, on May 08 – 10, 2017. BioTrinity is one of Europe’s leading biopartnering and investment conferences, and the largest of its type in the UK….

More

Selvita shows 19% business growth in 2016

Krakow, Poland – 20 April 2017 – Selvita, one of the largest drug discovery companies in Europe, has published annual financial results demonstrating its continued dynamic business performance across all segments. Net sales revenue in 2016 (excl. grants) amounted to PLN 48.1 MM, reflecting 17% growth compared with 2015, when…

More

Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget

Krakow, Poland – April 07, 2017 – Selvita, a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, leading Polish research and development institute focused on oncology, have jointly published most recent results of SEL120…

More

Selvita and Sandoz researchers publish paper on Tapentadol synthesis

Kraków, Poland – 08 March 2017 – Selvita and Sandoz researchers have recently jointly published a review on the “Evolution of synthetic routes towards homochiral Tapentadol“, which appeared in the Tetrahedron: Asymmetry, report number XX, on March 7.  The review encompasses analysis of the literature showing that the development of synthetic…

More

12345...10...